Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
UCSF - flucytosine
Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method
CrCl in mL/min where specified; no equation inferred.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Qualitative label versus institutional intervals; exactly 20 overlaps
ANCOBON emphasizes concentration-guided adjustment without a renal interval table. UCSF supplies intervals, but its printed 20-40 and 10-20 bands both include 20.
What to reconcile: Clarify the boundary and dosing weight with ID/pharmacy; retain serum-level and toxicity monitoring.
UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method: CrCl in mL/min where specified; no equation inferred. Source date: Revision date not stated in the reviewed page. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
The dose is 25 mg/kg orally at intervals determined by CrCl: >40 mL/min every 6 hours; 20-40 every 12 hours; 10-20 every 24 hours; <10 every 48 hours. The printed bands overlap at 20; clarify that endpoint rather than choosing silently.
Intermittent HD: 25 mg/kg initially and after HD. Continuous-HD dosing is not supplied; consult infectious diseases. Discuss single doses above 2000 mg with ID pharmacy.
UCSF uses ideal body weight unless actual weight is lower, and adjusted weight when actual weight exceeds 120% of ideal. Drug-level and toxicity monitoring are important when individualizing therapy.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.